This technology provides methods for synthesizing a group of naturally occurring compounds, syrbactins, and their derivatives, being of significant commercial value due to the ability of some of the members to inhibit proteasomal activity. TIR-199, for example, is one of the most potent proteasome inhibitors synthesized so far. The efficacy and efficiency of this novel drug candidate in inducing tumor cell death in multiple myeloma, neuroblastoma, and other types of cancer (e.g. kidney, colon, melanoma, ovarian) has been demonstrated using in vitro systems, cell lines, and animal models (reported for the first time for a syrbactin compound). TIR-199 drug candidate is ready for further pre-clinical and eventually clinical studies.  

Researchers at the University of California, Davis have developed a technology involving statistically reconstructing positronium (or positron) lifetime imaging (PLI) for use with a positron emission tomography (PET) scanner, to produce images having resolutions better than can be obtained with existing time-of-flight (TOF) systems.

Researchers at the University of California, Davis, have developed a novel imaging system that improves the diagnostic accuracy of PET imaging. The system combines machine learning and computed tomography (CT) imaging to reduce noise and enhance resolution. This novel technique can integrate with commercial PET imaging systems, improving diagnostic accuracy and facilitating superior treatment of various diseases.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

This novel technology enables refined temporal control of protein-protein interactions that can be used to regulate cell therapies, including CAR T-cells and “cell factories”.

High flux (e.g., greater than 1012 n/s/cm2) neutrons with energies between 8 and 30 MeV are needed for a number of applications including radioisotope production. However, none of the existing neutron sources available can fulfill these requirements. Neutron flux intensities from typical neutron sources using Deuterium-Tritium (DT) fusion are typically more than 2 orders of magnitude lower in intensity than what is needed for making production practical. Deuterium-Deuterium (DD) fusion sources provide a spectrum which is too low in energy to perform the nuclear reactions needed for isotope production. High-energy proton accelerator-driven spallation sources produce isotopes with significant co-production of unwanted radioisotopes, due to a neutron spectrum which is far higher in energy than required. While accelerator-driven neutron sources using deuteron breakup have been shown to be a viable pathway for producing a range of isotopes including actinium-225 1, a limited number of machines capable of producing ~30 MeV deuteron beams exist commercially. To address this problem, researchers at UC Berkeley have developed systems and methods for producing radionuclides using accelerator-driven fast neutron sources, and more specifically for producing actinium-225, an inherently-safe, fast neutron source based on low energy proton accelerators used throughout the world to support positron emission tomography.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed a technology providing the creation of stable analogs of glycosphingosines and gangliosides containing O-acetylated sialic acid for extensive biological and medical applications.

The invention entails a unique catheter device utilizing electromotive drug administration (EMDA) to enhance drug penetrance into tissues of the ureter, renal pelvis, and calyces. By incorporating a conductive wire and fluid delivery system, the catheter enables targeted drug delivery, potentially revolutionizing the treatment of kidney stones, urothelial carcinoma, infections, and inflammation without systemic side effects.

Researchers at the University of California, Davis have developed multi-specific antibody molecules including bi-specific and tri-specific antibodies that could serve to co-localize effector T-cells, target tumor B-cells and would simultaneously enhance anti-tumor activity and proliferation, whilst minimizing potential systemic toxicities

This patent application describes methods for non-invasive, label-free imaging of the cellular immune response in human skin using a nonlinear optical imaging system.

A novel method and device for high-throughput sorting of cells in suspension, particularly focusing on the separation of key cellular blood components of the immune system. The patent application presents a novel approach to high-throughput cell sorting, particularly suitable for applications in medicine and biotechnology where precise separation of cell populations is crucial.

The disclosed methods offer a robust approach to accurately quantify skin optical properties across different skin tones, facilitating improved diagnosis, monitoring, and treatment in dermatology.

Brief description not available

Researchers at the University of California, Davis have developed a unique peptide that induces cell differentiation by inhibiting cellular protein CHD4, a promising approach to target dedifferentiated cancer cells and for cell therapy.

Researchers at the University of California, Davis have identified a short peptide which rapidly promotes protein degradation in cancerous enzymes and induces cell differentiation to kill lymphomas.

Researchers at the University of California, Davis have developed a virally derived homolog to increase the inflammatory response desirable in cancer immunotherapy.

Researchers at the University of California, Davis have developed a viral peptide therapeutic that targets MYC-based cancerous tumors.